Evidence map›Paper›PMID 24427287›Full record

ArticlePloS one2014

Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.

Benjamin M Scott, Wadim L Matochko, Richard F Gierczak, Varsha Bhakta, Ratmir Derda, William P Sheffield

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Therapeutic SERPINs: Improving on Nature.Frontiers in cardiovascular medicine · 2021
    Review
  9. Engineering the serpin αProtein science : a publication of the Protein Society · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Benjamin M ScottDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Wadim L MatochkoDepartment of Chemistry, Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta, Canada.
Richard F GierczakDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Varsha BhaktaCanadian Blood Services, Research and Development, Hamilton, Ontario, Canada.
Ratmir DerdaDepartment of Chemistry, Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta, Canada.
William P SheffieldDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada ; Canadian Blood Services, Research and Development, Hamilton, Ontario, Canada.
McMaster University · CAAlberta Glycomics Centre · CACanadian Blood Services · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In spite of the power of phage display technology to identify variant proteins with novel properties in large libraries, it has only been previously applied to one member of the serpin superfamily. Here we describe phage display of human alpha-1 proteinase inhibitor (API) in a T7 bacteriophage system. API M358R fused to the C-terminus of T7 capsid protein 10B was directly shown to form denaturation-resistant complexes with thrombin by electrophoresis and immunoblotting following exposure of intact phages to thrombin. We therefore developed a biopanning protocol in which thrombin-reactive phages were selected using biotinylated anti-thrombin antibodies and streptavidin-coated magnetic beads. A library consisting of displayed API randomized at residues 357 and 358 (P2-P1) yielded predominantly Pro-Arg at these positions after five rounds of thrombin selection; in contrast the same degree of mock selection yielded only non-functional variants. A more diverse library of API M358R randomized at residues 352-356 (P7-P3) was also probed, yielding numerous variants fitting a loose consensus of DLTVS as judged by sequencing of the inserts of plaque-purified phages. The thrombin-selected sequences were transferred en masse into bacterial expression plasmids, and lysates from individual colonies were screening for API-thrombin complexing. The most active candidates from this sixth round of screening contained DITMA and AAFVS at P7-P3 and inhibited thrombin 2.1-fold more rapidly than API M358R with no change in reaction stoichiometry. Deep sequencing using the Ion Torrent platform confirmed that over 800 sequences were significantly enriched in the thrombin-panned versus naïve phage display library, including some detected using the combined phage display/bacterial lysate screening approach. Our results show that API joins Plasminogen Activator Inhibitor-1 (PAI-1) as a serpin amenable to phage display and suggest the utility of this approach for the selection of "designer serpins" with novel reactivity and/or specificity.

Indexed as

Cell Surface Display Techniquesalpha 1-AntitrypsinAmino Acid MotifsAmino Acid SequenceBacteriophagesCapsid ProteinsGene ExpressionGenetic VectorsHigh-Throughput Nucleotide SequencingHumansKineticsModels, MolecularPeptide LibraryProtein BindingProtein ConformationRecombinant Fusion Proteinsalpha 1-AntitrypsinCapsid ProteinsPeptide LibraryRecombinant Fusion ProteinsThrombin

Identifiers

PMID24427287
PMCPMC3888415
OpenAlexW2063660456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.